How long to take BPC-157, and does it need cycling?
Reviewed 20 sourcesPublished by PepVault
BPC-157 study lengths in one table: 14 to 90 days of daily dosing in rats, a 28-day safety study, 2 weeks with results in people. No study has tested a cycle.

- Last reviewed
- Sources
- 20
- Questions
- 6
- Compounds
- 1
The short answer
No study has tested a BPC-157 cycle, and no label sets a length, because it is approved nowhere. In rats it was given daily for the whole healing period, 14 to 90 days, and kept working through 3 months of daily dosing. The one repeat-dose safety study ran 28 days. In people, the longest course with results is 2 weeks.
Evidence: Animal research for every course length, mostly in rats from one Zagreb group; one 28-day repeat-dose safety study in rats and dogs; in people, single treatments and two enema studies of up to 2 weeks; no study of cycling or breaks in any species.

How long did the BPC-157 studies give it?
For as long as the injury took to heal, in almost every animal study. The rats got their first dose on the day of the injury and their last a day before the end of the study, so the course length is simply the study length. Here is every course length we could verify, with what each study found by its end. Six have their own study page, from the 2003 Achilles study (pepvault.app/research/bpc-157-staresinic-2003) to the 2024 bladder study (pepvault.app/research/bpc-157-lee-2024); all of them are at pepvault.app/research.
PepVault lets you give each compound a start and an end date. The protocol page then shows how far through the course you are and marks it complete once its last planned day has passed. Log it in PepVault
| Study | Species | How long | What it found by the end |
|---|---|---|---|
| Cut Achilles tendon, 20031 | Rats | Daily, 14 days | Stronger tendons and better function, checked on days 1, 4, 7, 10 and 14 |
| Repaired Achilles tendon, 20262 | Rats | Daily, 4 weeks | Stronger than untreated tendons, but not by a significant margin; TB-500 was |
| Gut fistula, 20243 | Rats | Daily or in water, up to 28 days | Every treated rat closed both openings |
| Muscle-tendon junction, 20214 | Rats | Daily or in water, up to 42 days | The defect closed, with well-ordered new tissue at 28 and 42 days |
| Cut thigh muscle, 20065 | Rats | Daily, 72 days | Healing better than untreated rats throughout |
| Cut knee ligament, 20106 | Rats | Daily, by injection, cream or water, 90 days | Healing better than untreated rats throughout |
| Liver damage from alcohol, 20017 | Rats | Daily for 3 months, or the last month only | Pressure in the liver's main vein back to healthy values either way |
| Repeat-dose safety, 20201011 | Rats, dogs | Daily, 28 days, then 14 days off | No serious toxicity reported; the FDA flagged clotting and liver signals |
| Knee pain, 20211113 | People, 16 | 1 or 2 injections | 7 of 12 given BPC-157 alone reported relief lasting over 6 months16 |
| Bladder pain, 202414 | People, 12 | One procedure | 10 of 12 reported their symptoms gone |
| Enema for ulcerative colitis, 200511 | People, 53 (half on placebo) | Daily, 2 weeks | The longest human course with results; known only from a meeting abstract |
| Gummy study, 202518 | People, 40 | Daily, 8 weeks | Finished in November 2025; no results posted |
| Shoulder surgery trial19 | People, 30 planned | Daily, 90 days | Set to start in January 2027 |
Every animal row is a lab schedule in rats or dogs, with amounts per kilogram of body weight. It describes the research, not a course for a person, and a result in a rat is not proof of one in people.
Two patterns stand out. The first is that the effect showed up early: in the Achilles study treated tendons were already stronger within the first two weeks1, and in the muscle-tendon study the repaired tissue was well ordered by day 284. The second is that the long studies kept reporting a benefit right to the end. The thigh muscle study reported better healing throughout 72 days5, and the ligament study throughout 906. No study stopped BPC-157 partway to see whether the gains held without it.
The one study that fell short came from a lab in Istanbul, outside the Zagreb group that discovered BPC-157: after 4 weeks its BPC-157 rats had stronger tendons than untreated rats, but the difference did not reach significance2.

What is the longest anyone has taken BPC-157 in a study?
In animals, 3 months of daily doses. In a 2001 study, rats drank alcohol every day for 3 months, and BPC-157 was given once a day either for the whole 3 months or only for the last month. Both schedules brought the raised pressure in the liver's main vein back to the values of healthy rats, so the treatment both prevented the damage and reversed it once it had set in7. A sister study in the same model found the same for stomach damage8.
In people, 2 weeks, among the studies with results. Of the five published human studies in the FDA's July 2026 review of BPC-157, only two gave it on more than two days, both as an enema, and neither went past two weeks11. Every other published human report is a single treatment or two: one procedure in the bladder14, one or two knee injections13, two infusions into a vein on two days15.
Three more human studies have no results yet. A tablet trial registered in Mexico in 2015 planned 2 weeks of doses every 8 hours and has posted no results17. A study of BPC-157 gummies in 40 active adults ran 8 weeks and finished in November 2025 with no results posted18. The University of Arkansas has registered the first placebo-controlled trial of daily injections under the skin, for 90 days after rotator cuff surgery, set to start in January 202719. Every human study is covered in detail at pepvault.app/guides/bpc-157-human-data.
Does BPC-157 need cycling?
Nobody has tested it. A cycle is a planned stretch on a compound followed by planned time off (pepvault.app/glossary/cycle). Our PubMed search on November 20, 2026 for BPC-157 with tolerance, tachyphylaxis, desensitization, withdrawal, cycling or long-term use found no study in any species that compared a course with breaks against one without, or measured BPC-157 working less over time.
The usual reason given for cycling is that a receptor stimulated nonstop starts to answer less, called tachyphylaxis (pepvault.app/glossary/tachyphylaxis). Seller pages apply that to BPC-157 without a study. The FDA's review names the gap in the argument: the molecular targets of BPC-157 have not been identified11. With no known receptor, there is nothing yet to measure wearing out.
What the animal data does show points the other way. In the alcohol study, rats dosed every day for 3 months did as well as those dosed for the last month only7. In a 1999 study of reflux damage to the gullet in rats whose stomach had been removed, BPC-157 in drinking water still protected the gullet at 1, 2 and 4 weeks, while two standard ulcer drugs, ranitidine and sucralfate, helped only at the first week9. And in rats and dogs given a dose every day for 7 days, the blood levels looked almost the same as after a single dose12, so it did not build up.
One more way a peptide can lose its effect is through antibodies. The FDA notes that peptides given under the skin or into the nose are more likely to set off an immune response, the body making antibodies against them (pepvault.app/glossary/immunogenicity), and that one possible result is a loss of effect. It found no study that has tested BPC-157 for this, by any route11.
So a break on BPC-157 is a choice, not a finding. People take one to see whether the injury holds without it and to limit time on a compound no one has studied for months, which are fair reasons of their own.
What did the 28-day safety study find?
It is the only study that gave BPC-157 every day to look for harm. A team in Xi'an, China gave it to rats and beagle dogs by injection into a muscle once a day for 28 days, then watched them for 14 more days with no doses1011. That 14-day stretch is a standard toxicology step to see whether any change reverses on its own. It is not a cycle, and it tested no restart.
The authors reported that BPC-157 was well tolerated, with no serious toxicity in mice, rats, rabbits or dogs. The one change they named, a lower creatinine level in dogs at the highest dose, went away on its own within the 2 weeks off10. The FDA read the same data closely and listed two signals: changes in clotting time (shorter in rats, longer in dogs) and liver-related changes in the blood, including the liver enzyme ALT, glucose and triglycerides11.
Its conclusion on length is the point for this question: no repeat-dose study longer than 28 days exists to show whether those findings repeat or whether new ones appear with longer use, and no cancer study has been done11. A 2026 review in the journal of the American Academy of Orthopaedic Surgeons reaches the same place: validated dosing and long-term safety data for BPC-157 are lacking20.
When to get help Bruising or bleeding that is unusual for you, or yellowing of the skin or eyes, during a course is a reason to see a doctor.
How long do people who use BPC-157 take it?
Commonly reported: courses of 4 to 12 weeks, often run until the injury settles and then stopped; some take a break of about the same length before another course; tendon and ligament pain easing within one to three weeks.
These are habits, not study results, and no published study has compared them. They sit inside the animal record's range of 2 to 13 weeks, and well past the 2 weeks with results in people. How soon users say it starts to work is at pepvault.app/peptides/bpc-157/how-long-to-work, timing within the day is at pepvault.app/guides/when-to-take-bpc-157, and the compound's full page is pepvault.app/peptides/bpc-157.
PepVault can pause a protocol between two dates: no doses come due and your consistency skips those days, then it resumes on its own. A days-on, days-off schedule is built in too. Set reminders in PepVault
What would settle how long to take it?
A trial in people that runs long enough and checks the tissue. The Arkansas rotator cuff study is the first built that way: 30 planned patients, BPC-157 or saline under the skin every day for 90 days, with the tendon checked by MRI19. It will give the first measured answer to whether a 90-day course heals a human tendon better than none. Whether a break changes anything will still be untested.
Sources
- Staresinic M et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003. PubMed 14554208
- Bicer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Jt Dis Relat Surg. 2026. PubMed 42542926
- Vukusic D et al. Duodenocolic fistula healing by pentadecapeptide BPC 157 in rats. A cytoprotection viewpoint. J Physiol Pharmacol. 2024. PubMed 38583442
- Japjec M et al. Stable gastric pentadecapeptide BPC 157 as a therapy for the disable myotendinous junctions in rats. Biomedicines. 2021. PubMed 34829776
- Staresinic M et al. Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157. J Orthop Res. 2006. PubMed 16609979
- Cerovecki T et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010. PubMed 20225319
- Prkacin I et al. Portal hypertension and liver lesions in chronically alcohol drinking rats prevented and reversed by stable gastric pentadecapeptide BPC 157 (PL-10, PLD-116), and propranolol, but not ranitidine. J Physiol Paris. 2001. PubMed 11595456
- Prkacin I et al. Chronic cytoprotection: pentadecapeptide BPC 157, ranitidine and propranolol prevent, attenuate and reverse the gastric lesions appearance in chronic alcohol drinking rats. J Physiol Paris. 2001. PubMed 11595453
- Sikiric P et al. Long-lasting cytoprotection after pentadecapeptide BPC 157, ranitidine, sucralfate or cholestyramine application in reflux oesophagitis in rats. J Physiol Paris. 1999. PubMed 10672991
- Xu C et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020. PubMed 32334036
- U.S. Food and Drug Administration. Briefing document for BPC-157-related bulk drug substances, Pharmacy Compounding Advisory Committee meeting, July 23-24, 2026. fda.gov
- He L et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022. PubMed 36588717
- Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021. PubMed 34324435
- Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024. PubMed 39325560
- Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025. PubMed 40131143
- Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025. PubMed 40756949
- ClinicalTrials.gov NCT02637284. PCO-02: safety and pharmacokinetics trial. PharmaCotherapia. clinicaltrials.gov
- ClinicalTrials.gov NCT07752381. A clinical trial to evaluate the effects of peptide gummies on markers of inflammation, physical performance, and recovery. clinicaltrials.gov
- ClinicalTrials.gov NCT07803250. Impact of BPC-157 on recovery following rotator cuff repair surgery. University of Arkansas. clinicaltrials.gov
- Tham A, Hodgkins CW, Kennedy JG. Investigational peptides in orthopaedic practice: evidence, safety, and patient counseling for BPC-157, thymosin beta-4, and TB-500. J Am Acad Orthop Surg. 2026. PubMed 42937313
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.